APA (7th ed.) Citation

M, M., EL, G., E, H., SWJ, Z., TT, S., IME, D., . . . ADR, H. (2025). Pharmacokinetic exposure and treatment outcomes of lenvatinib in patients with renal cell carcinoma and differentiated thyroid carcinoma. Cancer chemotherapy and pharmacology, 95(1), 25. https://doi.org/10.1007/s00280-024-04746-5

Chicago Style (17th ed.) Citation

M, Meertens, et al. "Pharmacokinetic Exposure and Treatment Outcomes of Lenvatinib in Patients with Renal Cell Carcinoma and Differentiated Thyroid Carcinoma." Cancer Chemotherapy and Pharmacology 95, no. 1 (2025): 25. https://doi.org/10.1007/s00280-024-04746-5.

MLA (9th ed.) Citation

M, Meertens, et al. "Pharmacokinetic Exposure and Treatment Outcomes of Lenvatinib in Patients with Renal Cell Carcinoma and Differentiated Thyroid Carcinoma." Cancer Chemotherapy and Pharmacology, vol. 95, no. 1, 2025, p. 25, https://doi.org/10.1007/s00280-024-04746-5.